Tempo and mode of inhibitor-mutagen antiviral therapies: A multidisciplinary approach

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 38, 2011, Pages 16008-16013

  Iranzo, Jaime ^a   Perales, Celia ^b,c   Domingo, Esteban ^b,c   Manrubia, Susanna C ^a  

^a CENTRO DE ASTROBIOLOGÍA CSIC INTA   (Spain)

^b CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antiviral design; Mutation; Population dynamics; Viral adaptation; Viral quasispecies

Indexed keywords

GUANIDINE; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; COMPUTER MODEL; DRUG RESPONSE; DYNAMICS; FOOT AND MOUTH DISEASE VIRUS; IN VITRO STUDY; NONHUMAN; OPTIMAL DRUG DOSE; POPULATION; PREDICTION; PRIORITY JOURNAL; VIRAL POPULATION; VIRUS; VIRUS REPLICATION;

ALGORITHMS; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; FOOT-AND-MOUTH DISEASE VIRUS; GUANIDINE; MODELS, BIOLOGICAL; MUTAGENS; MUTATION; RIBAVIRIN; TIME FACTORS; VIRUS REPLICATION;

FOOT-AND-MOUTH DISEASE VIRUS; PICORNAVIRIDAE;

EID: 80053158199     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1110489108     Document Type: Article

References (39)

1. Richman DD, ed (1996) Antiviral Drug Resistance (Wiley, New York).
2. Domingo E, et al. (1997) Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog Drug Res 48:99-128. (Pubitemid 27242826)
3. Endy D, Yin J (2000) Toward antiviral strategies that resist viral escape. Antimicrob Agents Chemother 44:1097-1099. (Pubitemid 30165301)
4. Vignuzzi M, Wendt E, Andino R (2008) Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med 14:154-161. (Pubitemid 351214560)
5. Domingo E, Grande-Pérez A, Martín V (2008) Future prospects for the treatment of rapidly evolving viral pathogens: Insights from evolutionary biology. Expert Opin Biol Ther 8:1455-1460.
6. Keith CT, Borisy AA, Stockwell BR (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4:71-78. (Pubitemid 40109591)
7. Torella JP, Chait R, Kishony R (2010) Optimal drug synergy in antimicrobial treatments. PLoS Comput Biol 6:e1000796.
8. Handel A, Regoes RR, Antia R (2006) The role of compensatory mutations in the emergence of drug resistance. PLoS Comput Biol 2:e137.
9. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2:458-466. (Pubitemid 44266307)
10. Yeh P, Tschumi AI, Kishony R (2006) Functional classification of drugs by properties of their pairwise interactions. Nat Genet 38:489-494.
11. Bonhoeffer S, May RM, Shaw GM, Nowak MA (1997) Virus dynamics and drug therapy. Proc Natl Acad Sci USA 94:6971-6976. (Pubitemid 27281975)
12. Komarova NL, Barnes E, Klenerman P, Wodarz D (2003) Boosting immunity by antiviral drug therapy: A simple relationship among timing, efficacy, and success. Proc Natl Acad Sci USA 100:1855-1860. (Pubitemid 36254538)
13. Pariente N, Airaksinen A, Domingo E (2003) Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol 77:7131-7138. (Pubitemid 36666908)
14. Pariente N, Sierra S, Airaksinen A (2005) Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus. Virus Res 107:183-193. (Pubitemid 40093091)
15. Perales C, Mateo R, Mateu MG, Domingo E (2007) Insights into RNA virus mutant spectrum and lethal mutagenesis events: Replicative interference and complementation by multiple point mutants. J Mol Biol 369:985-1000. (Pubitemid 46754065)
16. González-López C, Arias A, Pariente N, Gómez-Mariano G, Domingo E (2004) Preextinction viral RNA can interfere with infectivity. J Virol 78:3319-3324. (Pubitemid 38568272)
17. Eigen M, Schuster P (1979) The Hypercycle. A Principle of Natural Self-Organization (Springer, Berlin).
18. Eigen M (2002) Error catastrophe and antiviral strategy. Proc Natl Acad Sci USA 99: 13374-13376.
19. Domingo E, Escarmís C, Lázaro E, Manrubia SC (2005) Quasispecies dynamics and RNA virus extinction. Virus Entry into Error Catastrophe as a New Antiviral Strategy, ed E. Domingo. Virus Res 107:129-139.
20. Lee CH, et al. (1997) Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus. J Virol 71:3636-3640. (Pubitemid 27172375)
21. Crotty S, Cameron CE, Andino R (2001) RNA virus error catastrophe: Direct molecular test by using ribavirin. Proc Natl Acad Sci USA 98:6895-6900. (Pubitemid 32538313)
22. Manrubia SC, Domingo E, Lázaro E (2010) Pathways to extinction: Beyond the error threshold. Philos Trans R Soc Lond B Biol Sci 365:1943-1952.
23. Cases-González C, Arribas M, Domingo E, Lázaro E (2008) Beneficial effects of population bottlenecks in an RNA virus evolving at increased error rate. J Mol Biol 384: 1120-1129.
24. Perales C, Agudo R, Tejero H, Manrubia SC, Domingo E (2009) Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog 5: e1000658.
25. Domingo E, Holland JJ (1992) Complications of RNA heterogeneity for the engineering of virus vaccines and antiviral agents. Genetic Engineering, Principles and Methods, ed Setlow JK (Plenum, New York), Vol 14, pp 13-31.
26. Ho DD (1995) Time to hit HIV, early and hard. N Engl J Med 333:450-451.
27. Domingo E (1989) RNA virus evolution and the control of viral disease. Prog Drug Res 33:93-133.
28. Nijhuis M, Van Maarseveen NM, Boucher CA (2009) Handbook of Experimental Pharmacology (Springer, Berlin), pp 299-320.
29. Ribeiro RM, Bonhoeffer S (2000) Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci USA 97:7681-7686. (Pubitemid 30460706)
30. Müller V, Bonhoeffer S (2008) Origin and Evolution of Viruses, eds Domingo E, Parrish CR, Holland JJ (Academic, London), 2nd Ed, pp 279-302.
31. Von Kleist M, et al. (2011) HIV quasispecies dynamics during pro-active treatment switching: Impact on multi-drug resistance and resistance archiving in latent reservoirs. PLoS One 6:e18204.
32. Geller R, Vignuzzi M, Andino R, Frydman J (2007) Evolutionary constraints on chaperone- mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev 21:195-205. (Pubitemid 46155813)
33. Perales C, Agudo R, Domingo E (2009) Counteracting quasispecies adaptability: Extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS One 4:e5554.
34. Ruiz-Jarabo CM, Ly C, Domingo E, De la Torre JC (2003) Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308: 37-47. (Pubitemid 36432114)
35. Mullins JI, et al. (2011) Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS One 6:e15135.
36. Domingo E, Dávila M, Ortín J (1980) Nucleotide sequence heterogeneity of the RNA from a natural population of foot-and-mouth-disease virus. Gene 11:333-346. (Pubitemid 11215356)
37. Sobrino F, Dávila M, Ortín J, Domingo E (1983) Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology 128: 310-318. (Pubitemid 13048816)
38. García-Arriaza J, Manrubia SC, Toja M, Domingo E, Escarmís C (2004) Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol 78: 11678-11685.
39. Toja M, Escarmís C, Domingo E (1999) Genomic nucleotide sequence of a foot-andmouth disease virus clone and its persistent derivatives. Implications for the evolution of viral quasispecies during a persistent infection. Virus Res 64:161-171. (Pubitemid 29460725)